Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content.

Bell LN, Temm CJ, Saxena R, Vuppalanchi R, Schauer P, Rabinovitz M, Krasinskas A, Chalasani N, Mattar SG.

Ann Surg. 2010 Jun;251(6):1041-8. doi: 10.1097/SLA.0b013e3181dbb572.

2.

Hepatic lipid peroxidation and cytochrome P-450 2E1 in pediatric nonalcoholic fatty liver disease and its subtypes.

Bell LN, Molleston JP, Morton MJ, Klipsch A, Saxena R, Vuppalanchi R, Chalasani N.

J Clin Gastroenterol. 2011 Oct;45(9):800-7. doi: 10.1097/MCG.0b013e31821377e4.

3.

CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis.

Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR.

J Clin Invest. 2000 Apr;105(8):1067-75.

4.

CYP2E1 potentiates binge alcohol-induced gut leakiness, steatohepatitis, and apoptosis.

Abdelmegeed MA, Banerjee A, Jang S, Yoo SH, Yun JW, Gonzalez FJ, Keshavarzian A, Song BJ.

Free Radic Biol Med. 2013 Dec;65:1238-45. doi: 10.1016/j.freeradbiomed.2013.09.009. Epub 2013 Sep 21.

5.

Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis.

Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C.

Hepatology. 1998 Jan;27(1):128-33.

PMID:
9425928
6.

CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease.

Emery MG, Fisher JM, Chien JY, Kharasch ED, Dellinger EP, Kowdley KV, Thummel KE.

Hepatology. 2003 Aug;38(2):428-35.

PMID:
12883487
7.

Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.

Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Bhanot S, Monia BP, Li YX, Diehl AM.

Hepatology. 2007 Jun;45(6):1366-74.

PMID:
17476695
8.

Hepatic cytochrome P450 2E1 activity in nonalcoholic fatty liver disease.

Prompila N, Wittayalertpanya S, Komolmit P.

J Med Assoc Thai. 2008 May;91(5):733-8.

PMID:
18672640
9.

Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role.

Aubert J, Begriche K, Knockaert L, Robin MA, Fromenty B.

Clin Res Hepatol Gastroenterol. 2011 Oct;35(10):630-7. doi: 10.1016/j.clinre.2011.04.015. Epub 2011 Jun 12. Review.

PMID:
21664213
10.

Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseases.

Niemelä O, Parkkila S, Juvonen RO, Viitala K, Gelboin HV, Pasanen M.

J Hepatol. 2000 Dec;33(6):893-901.

PMID:
11131450
11.

Overexpression of liver-specific cytochrome P4502E1 impairs hepatic insulin signaling in a transgenic mouse model of nonalcoholic fatty liver disease.

Kathirvel E, Morgan K, French SW, Morgan TR.

Eur J Gastroenterol Hepatol. 2009 Sep;21(9):973-83. doi: 10.1097/MEG.0b013e328328f461.

PMID:
19307976
12.

Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis.

Abdelmegeed MA, Banerjee A, Yoo SH, Jang S, Gonzalez FJ, Song BJ.

J Hepatol. 2012 Oct;57(4):860-6. doi: 10.1016/j.jhep.2012.05.019. Epub 2012 Jun 2.

13.

Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients.

Videla LA, Rodrigo R, Orellana M, Fernandez V, Tapia G, Quiñones L, Varela N, Contreras J, Lazarte R, Csendes A, Rojas J, Maluenda F, Burdiles P, Diaz JC, Smok G, Thielemann L, Poniachik J.

Clin Sci (Lond). 2004 Mar;106(3):261-8.

PMID:
14556645
14.

[Correlation between hepatocyte cytochrome P450IIE1 expression and oxidation, antioxidation in rat nonalcoholic steatosis model].

Dai N, Zeng M, Li J.

Zhonghua Gan Zang Bing Za Zhi. 1999 Jun;7(2):104-6. Chinese.

PMID:
10488421
15.

Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis.

Chalasani N, Gorski JC, Asghar MS, Asghar A, Foresman B, Hall SD, Crabb DW.

Hepatology. 2003 Mar;37(3):544-50.

PMID:
12601351
16.

Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis.

Chtioui H, Semela D, Ledermann M, Zimmermann A, Dufour JF.

Liver Int. 2007 Aug;27(6):764-71.

PMID:
17617119
17.

Environmental toxin-linked nonalcoholic steatohepatitis and hepatic metabolic reprogramming in obese mice.

Seth RK, Kumar A, Das S, Kadiiska MB, Michelotti G, Diehl AM, Chatterjee S.

Toxicol Sci. 2013 Aug;134(2):291-303. doi: 10.1093/toxsci/kft104. Epub 2013 May 2.

18.

Early alcoholic liver injury: formation of protein adducts with acetaldehyde and lipid peroxidation products, and expression of CYP2E1 and CYP3A.

Niemelä O, Parkkila S, Pasanen M, Iimuro Y, Bradford B, Thurman RG.

Alcohol Clin Exp Res. 1998 Dec;22(9):2118-24.

PMID:
9884160
19.

Lipid peroxidation in bariatric candidates with nonalcoholic fatty liver disease (NAFLD) -- preliminary findings.

Oliveira CP, Faintuch J, Rascovski A, Furuya CK Jr, Bastos Mdo S, Matsuda M, Della Nina BI, Yahnosi K, Abdala DS, Vezozzo DC, Alves VA, Zilberstein B, Garrido AB Jr, Halpern A, Carrilho FJ, Gama-Rodrigues JJ.

Obes Surg. 2005 Apr;15(4):502-5.

PMID:
15946429
20.

CYP2E1-dependent and leptin-mediated hepatic CD57 expression on CD8+ T cells aid progression of environment-linked nonalcoholic steatohepatitis.

Seth RK, Das S, Kumar A, Chanda A, Kadiiska MB, Michelotti G, Manautou J, Diehl AM, Chatterjee S.

Toxicol Appl Pharmacol. 2014 Jan 1;274(1):42-54. doi: 10.1016/j.taap.2013.10.029. Epub 2013 Nov 7.

Supplemental Content

Support Center